金币
UID430913
帖子
主题
积分4892
注册时间2019-3-4
最后登录1970-1-1
听众
性别保密
|
发表于 2024-5-13 16:01:02
|
显示全部楼层
需要,FDA针对提出过缺陷
You manufacture multiple API listed in the United States Pharmacopeia (USP) that were imported into the United States and supplied to compounding pharmacies. For (b)(4) API, the laboratory stability protocols used to support expiration dating of these API are based on methods and specifications in the 2015 Chinese Pharmacopeia. You were not able to demonstrate that the tests used are equivalent to or better than the current USP 42 compendial methods. FDA compared your test methods, based on the Chinese Pharmacopeia, to the current standard in the USP. We found multiple differences in specifications and test methods. We also found that required tests for quality attributes in the USP were not part of the Chinese Pharmacopeia or your stability protocols. Beyond a deviation from CGMP, this also causes your drugs to be adulterated within the meaning of 501(b) of the FD&C Act, 21 U.S.C. 351(b), in that their strength, quality, or purity falls below the standards set forth in an official compendium recognized in the FD&C Act.
你们生产多个进口到美国并供应给药房的美国药典 (USP) 级 API,但用于支持这些 API 有效期的实验室稳定性方案是基于 2015 版中国药典中的方法和规范制定的。你们无法证明所使用的测试等效或优于当前的 USP 42 药典方法。FDA将中国药典的测试方法与USP中的现行标准进行了比较。我们发现标准和测试方法存在多个差异。我们还发现,USP 中必需测试的质量属性不包括在中国药典或你们的稳定性方案中。除了偏离CGMP之外,这也会导致你们的药物根据FD&C法案,21 U.S.C. 351(b)被认定为掺假,因为药物的强度、质量或纯度低于官方规定的标准。 |
|